Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Active not recruiting 3Recruiting 1

Sponsor Class

OTHER 49INDUSTRY 38NETWORK 4OTHER_GOV 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Adenocarcinoma 1

Interventions

Radiotherapy 34Gemcitabine 24Docetaxel 24bicalutamide 23Goserelin 21Paclitaxel 19Cisplatin 19Doxorubicin 18Carboplatin 18Flutamide 17Leuprolide 16Radiotherapy, Conformal 13Etoposide 13Filgrastim 12Prednisone 11Gene Expression Profiling 11Gonadotropin-Releasing Hormone 10Radiotherapy, Intensity-Modulated 9Vincristine 8Vinblastine 8Triptorelin Pamoate 8Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Buserelin 8Androgen Antagonists 8Surgical Procedures, Operative 7Radiation 7Polymerase Chain Reaction 7Methotrexate 7Estramustine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NETWORK × darolutamide × Genitourinary × Clear all
NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
27 enrolled
Genitourinary

Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting
830 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT02972060 2025-09-19

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting
61 enrolled
Genitourinary

Prostatic Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Canadian Cancer Trials Group

Phase 2 Active not recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡